Evidence map›Paper›PMID 29689709›Full record

ArticleCancer biomarkers : section A of Disease markers2018

A blood biomarker for monitoring response to anti-EGFR therapy.

Nicholas P Hughes, Lingyun Xu, Carsten H Nielsen, Edwin Chang, Sharon S Hori, Arutselvan Natarajan, Samantha Lee, Andreas Kjær, Kian Kani, Shan X Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Nicholas P HughesMolecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Lingyun XuMolecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Carsten H NielsenMolecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Edwin ChangMolecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Sharon S HoriMolecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Arutselvan NatarajanMolecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Samantha LeeCanary Center at Stanford for Cancer Early Detection, Palo Alto, CA, USA.
Andreas KjærDepartment of Clinical Physiology, Nuclear Medicine and PET, Center for Diagnostic Investigations, Rigshospitalet, Copenhagen, Denmark.
Kian KaniLawrence J. Ellison Institute of Transformative Medicine, University of Southern California, Los Angeles, CA, USA.
Shan X WangDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Parag MallickMolecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Sanjiv Sam GambhirMolecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Stanford University · USRigshospitalet · DKUniversity of Copenhagen · DKUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveTo monitor therapies targeted to epidermal growth factor receptors (EGFR) in non-small cell lung cancer (NSCLC), we investigated Peroxiredoxin 6 (PRDX6) as a biomarker of response to anti-EGFR agents.

methodsWe studied cells that are sensitive (H3255, HCC827) or resistant (H1975, H460) to gefitinib. PRDX6 was examined with either gefitinib or vehicle treatment using enzyme-linked immunosorbent assays. We created xenograft models from one sensitive (HCC827) and one resistant cell line (H1975) and monitored serum PRDX6 levels during treatment.

resultsPRDX6 levels in cell media from sensitive cell lines increased significantly after gefitinib treatment vs. vehicle, whereas there was no significant difference for resistant lines. PRDX6 accumulation over time correlated positively with gefitinib sensitivity. Serum PRDX6 levels in gefitinib-sensitive xenograft models increased markedly during the first 24 hours of treatment and then decreased dramatically during the following 48 hours. Differences in serum PRDX6 levels between vehicle and gefitinib-treated animals could not be explained by differences in tumor burden.

conclusionsOur results show that changes in serum PRDX6 during the course of gefitinib treatment of xenograft models provide insight into tumor response and such an approach offers several advantages over imaging-based strategies for monitoring response to anti-EGFR agents.

Indexed as

AnimalsAntineoplastic AgentsBiomarkersCarcinoma, Non-Small-Cell LungCell Line, TumorDisease Models, AnimalEnzyme-Linked Immunosorbent AssayErbB ReceptorsFemaleGefitinibHumansLung NeoplasmsMicePeroxiredoxin VIProtein Kinase InhibitorsQuinazolinesAntineoplastic AgentsBiomarkersErbB ReceptorsGefitinibPeroxiredoxin VIPRDX6 protein, humanProtein Kinase InhibitorsQuinazolinesEGFRELISAgefitinibNSCLCproteomicsSerum biomarkers

Identifiers

PMID29689709
PMCPMC13078425
OpenAlexW2800351233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.